Teva Pharmaceutical Industries (TEVA)
(Delayed Data from NYSE)
$17.46 USD
-0.21 (-1.19%)
Updated Oct 2, 2024 04:00 PM ET
After-Market: $17.41 -0.05 (-0.29%) 6:50 PM ET
3-Hold of 5 3
A Value B Growth C Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$17.46 USD
-0.21 (-1.19%)
Updated Oct 2, 2024 04:00 PM ET
After-Market: $17.41 -0.05 (-0.29%) 6:50 PM ET
3-Hold of 5 3
A Value B Growth C Momentum A VGM
Zacks News
Why Teva Pharmaceutical Industries Ltd. (TEVA) is Poised to Beat Earnings Estimates Again
by Zacks Equity Research
Teva Pharmaceutical Industries Ltd. (TEVA) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Eli Lilly (LLY) Gets FDA Nod for Migraine Drug Emgality
by Zacks Equity Research
Eli Lilly's (LLY) CGRP antibody Emgality injection gains an FDA approval for the preventive treatment of migraine in adults.
Forget Mylan, Invest in These 3 Generic/Drug Stocks Instead
by Ekta Bagri
Given the recent spate of setbacks suffered by Mylan (MYL), we suggest investing in better-ranked generic/drug companies with favorable growth profile.
Lilly's Migraine Drug Emgality Wins Positive CHMP Opinion
by Zacks Equity Research
Eli Lilly's (LLY) CGRP antibody Emgality gains a positive view from CHMP for the treatment of migraine in adults, who encounter minimum four migraine spells a month.
AbbVie/Roche's Leukemia Drugs Combo Gets CHMP Backing in EU
by Zacks Equity Research
The CHMP gives positive opinion for combination use of AbbVie's (ABBV) Venclexta and Roche's Rituxan for relapsed/refractory CLL in patients who have received at least one prior therapy.
AstraZeneca's Fasenra Long-Term Asthma Study Data Positive
by Zacks Equity Research
AstraZeneca's (AZN) asthma drug, Fasenra, maintains improvements achieved over first year of treatment in severe eosinophilic asthma patients for the next 56 weeks.
Regeneron Gains on Eylea, Dupixent and Pipeline Progress
by Zacks Equity Research
Solid performance of approved drugs like Eylea and Dupixent along with an encouraging pipeline progress improve Regeneron's (REGN) market position.
New Marijuana Stocks? & Earnings from ORCL and FDX | Free Lunch
by Ryan McQueeney
Ryan McQueeney touches on the trade war's latest tariff threats and a key FDA approval for Teva Pharmaceuticals. He also highlights two surprising companies which might have a chance to profit from the marijuana boom. Later, Ryan previews Oracle and FedEx's earnings reports.
Teva's (TEVA) Migraine Drug Ajovy Receives FDA Approval
by Zacks Equity Research
Teva Pharmaceutical's (TEVA) anti-CGRP drug, Ajovy, gets FDA nod as a preventive treatment of migraine in adult patients.
Allergan Frown Lines Study Passes Test on Higher Botox Dose
by Zacks Equity Research
Allergan (AGN) presents positive results from a study, evaluating a higher dose of Botox for the treatment of glabellar lines.
Regeneron-Sanofi Report Data on Dupixent in Atopic Dermatitis
by Zacks Equity Research
Regeneron (REGN) and partner Sanofi present encouraging data from a late-stage trial on dermatitis drug Dupixent in adolescents.
Acorda (ACOR) Stock Dips, FDA Delays Decision on Inbrija
by Zacks Equity Research
The FDA defers decision by three months regarding the NDA of Acorda's (ACOR) Parkinson's disease candidate Inbrija for the treatment of OFF periods.
AbbVie Gets FDA Nod for Venclexta Label Expansion in Leukemia
by Zacks Equity Research
AbbVie (ABBV) gets FDA approval to include MRD-negativity (undetectable disease) data from phase III MURANO study on the label of Venclexta.
Acorda Gets Unfavorable Court Ruling for Ampyra, Stock Down
by Zacks Equity Research
Acorda Therapeutics' (ACOR) stock slumps after a Federal Circuit Court rules against its appeal to protect patents pertaining to its key multiple sclerosis drug, Ampyra
Lilly, Teva, Pfizer & Others Await FDA Decisions in September
by Kinjel Shah
FDA grants approval to 34 new treatments this year so far.
Mylan Suffers Several Setbacks: What's in Store in 2H18?
by Zacks Equity Research
Mounting competition and recent setbacks cast a pall over Mylan's (MYL) near-term performance.
AbbVie's Imbruvica Combo Gets FDA Nod for Rare Lymphoma
by Zacks Equity Research
AbbVie's (ABBV) cancer drug Imbruvica gets FDA approval for use in combination with Roche's Rituxan for Waldenstrom's macroglobulinemia (WM), a rare form of Non-Hodgkin's lymphoma.
5 Reasons Why You Should Add Lilly Stock to Your Portfolio
by Zacks Equity Research
Here are five reasons which investors may consider while investing in Lilly's (LLY) stock.
Biotech Stock Roundup: Label Expansion of Regeneron's Eylea, Vertex's Kalydeco
by Zacks Equity Research
The biotech sector witnesses a pretty low key week with a handful of regulatory updates. Regeneron secures an FDA approval for the label expansion of its key drug Eylea.
Mylan Suffers a Blow as Teva Gets FDA Nod for EpiPen Generic
by Zacks Equity Research
Mylan (MYL) suffers another setback as Teva wins the FDA approval of first generic version of EpiPen and EpiPen Jr (epinephrine) auto-injector for the emergency treatment of allergic reactions.
Teva Gets FDA Nod for First Generic Version of Mylan's EpiPen
by Zacks Equity Research
Teva (TEVA) gains FDA approval for the first generic version of Mylan's (MYL) popular EpiPen (epinephrine) auto-injector for severe allergy treatment.
Regeneron, Teva Announce Positive Data on Osteoarthritis Drug
by Zacks Equity Research
Regeneron (REGN) along with partner Teva announces positive top-line results from a late-stage candidate on fasinumab in patients with chronic pain from osteoarthritis of the knee or hip.
Invest Like Buffett & Berkshire With These Top Stock Picks
by Benjamin Rains
Warren Buffett has for years been looked at as an investment icon, while maintaining a relatively simple mantra. Buffett and Berkshire Hathaway (BRK.B) have long tried to invest in companies that both the Oracle of Omaha and the conglomerate understand. This sounds easy enough, but what are some of Buffett's most recent investments?
Here's Why Lilly (LLY) Stock is Up 15% Since Q2 Earnings
by Zacks Equity Research
Eli Lilly's (LLY) stock is up 15% since announcement of earnings in July. Let us have a look at the reasons for the same.
BioDelivery (BDSI) Q2 Loss Narrows, Sales Miss, Shares Down
by Zacks Equity Research
BioDelivery Sciences (BDSI) reports narrower-than-expected loss in Q2. Sales marginally miss the consensus mark.